1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Biomarkers Definitions Working Group;Clin Pharmacol Ther,2001
2. The promise and peril of surrogate end points in cancer research;Schatzkin;Nat Rev Cancer,2002
3. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2;Bailey;Proc Am Assoc Cancer Res,2003
4. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib;Hirsch;Ann Oncol,2007